title: [The effect of cytomedines on the hemostatic and antioxidant potential of patients in the early stage of diabetic retinopathy].
abstract: Epithalamine produces a dose-dependent antioxidant effect in patients in the early stage of diabetic retinopathy (DR). Retinalamine normalizes the parameters of local hemostatic potential only under the conditions of completely restored antioxidant activity and lipid hydroperoxide level. Combined administration of epithalamine and retinalamine is recommended for correcting pathological changes of the hemostatic and antioxidant potential and for preventing the blood vessel damage in patients in the early stage of DR.
authors.forename: N A
authors.initials: NA
authors.lastname: Gavrilova
authors.forename: T N
authors.initials: TN
authors.lastname: Fedorova
authors.forename: S V
authors.initials: SV
authors.lastname: Trofimova
authors.forename: I V
authors.initials: IV
authors.lastname: Pimenov
authors.forename: N I
authors.initials: NI
authors.lastname: Lanevskaia
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage; D000975:Antioxidants / Q000008:administration & dosage*; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006401:Hematologic Agents / Q000008:administration & dosage*; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D007273:Injections, Intramuscular; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction / Q000187:drug effects; D010455:Peptides / Q000008:administration & dosage*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage
chemical_list: D000925:Anticoagulants; D000975:Antioxidants; D005343:Fibrinolytic Agents; D006401:Hematologic Agents; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; C503555:retinalamin; C027437:epithalamin